Tariff Threat Intensifies Novo Nordisk's U.S. Pricing Crisis

What happened

The Trump administration is preparing tariffs up to 100% on branded drugs from pharmaceutical companies like Novo Nordisk that haven't struck deals to lower U.S. prices, as reported by CNBC. This emerges as Novo's filings confirm U.S. net prices declined in 2025, with management expecting continued pressure in 2026, and the company has already lost weekly prescription leadership to Eli Lilly's GLP-1 products. Novo's strategy relies on access actions and a planned 2027 list-price reset to offset pricing erosion, but tariffs could force deeper concessions or restrict market access prematurely. The DeepValue report notes that policy risks, including Medicare negotiations, are already headwinds, and this tariff threat adds a more immediate, punitive layer that could accelerate gross-to-net compression. Thus, external political pressure now directly challenges Novo's ability to stabilize U.S. economics through volume growth alone.

Implication

Investors must weigh that tariffs could force Novo to accept steeper rebates or lose formulary positions, directly impacting 2026 guidance for adjusted operating profit declines of 5-13%. This external shock may accelerate competitive share losses, as Eli Lilly's products could gain an edge if Novo faces tariff-induced cost pressures. Financially, the non-recurring $4.2 billion 340B revenue recognition in Q1 2026 becomes less protective against sustained margin erosion from tariffs. Monitoring should now include political developments and Novo's response, such as potential deal-making with the administration to avoid tariffs, which could itself entail further price concessions. Overall, this elevates the urgency for evidence of U.S. stabilization, making the wait-and-see approach riskier without clearer near-term catalysts.

Thesis delta

The DeepValue report's thesis of waiting for U.S. net price stabilization and script re-acceleration by Q2 2026 now faces an amplified policy threat that could hasten negative outcomes. Tariffs specifically target Novo's U.S. reliance, potentially worsening the bear case probability from 25% and lowering the attractive entry point below $34. Investors should reassess the 3-6 month window, as political uncertainty adds volatility and may require faster exit if tariff implementation becomes likely.